Telomerase as a useful target in cancer fighting - The breast cancer case

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1371-1380

  Holysz, Hanna ^a   Lipinska, Natalia ^a   Paszel Jaworska, Anna ^a   Rubis, Blazej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adenocarcinoma; Breast cancer; Telomerase; Telomere; Therapy

Indexed keywords

2 (3 NAPHTHALEN 2 YL BUT 2 ENOYLAMINO)BENZOID ACID; ANTINEOPLASTIC AGENT; BIBR 1532; BUTEIN; CANCER VACCINE; DOXORUBICIN; GEFITINIB; GENISTEIN; GRNVAC1 VACCINE; GRNVAC2 VACCINE; IMETELSTAT; PECTENOTOXIN 2; RETINOIC ACID; SMALL INTERFERING RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER PREVENTION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HUMAN; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TERT GENE; TRANSCRIPTION REGULATION;

EID: 84878686869     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0757-4     Document Type: Review

References (121)

1. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.
2. Dimri GP. What has senescence got to do with cancer? Cancer Cell. 2005;7:505-12.
3. Narita M, Lowe SW. Senescence comes of age. Nat Med. 2005;11:920-2.
4. Uziel O, Beery E, Dronichev V, Samocha K, et al. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. PLoS One. 2010;5:e9132.
5. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis. 2003;24:1167-76.
6. Papanikolaou V, Athanassiou E, Dubos S, Dimou I, et al. hTERT regulation by NF-kappaB and c-myc in irradiated HER2-positive breast cancer cells. Int J Radiat Biol. 2011;87:609-21.
7. Li AY, Lin HH, Kuo CY, Shih HM, et al. High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. Mol Cell Biol. 2011;31:2605-17.
8. Donate LE, Blasco MA. Telomeres in cancer and ageing. Philos Trans R Soc Lond B Biol Sci. 2011;366:76-84.
9. Park KD, Seong SK, Park YM, Choi Y, et al. Telomerase reverse transcriptase related with telomerase activity regulates tumorigenic potential of mouse embryonic stem cells. Stem Cells Dev. 2011;20:149-57.
10. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature. 2010;464:520-8.
11. Wang X, Hao MW, Dong K, Lin F, et al. Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharm Res. 2009;32:1263-9.
12. Li X, Liu Y, Wen Z, Li C, et al. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer. 2010;9:10.
13. Rahman R, Grundy R. Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. Int J Cancer. 2011;12:2765-74.
14. Lu Y, Gu J, Jin D, Gao Y, et al. Inhibition of telomerase activity by HDV ribozyme in cancers. J Exp Clin Cancer Res. 2011;30:1.
15. Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer. 1997;33:781-6.
16. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-91.
17. Bryan TM, Englezou A, Gupta J, Bacchetti S, et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240-8.
18. Cerone MA, Londono-Vallejo JA, Autexier C. Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance. Oncogene. 2006;25:7411-20.
19. Wang Z, Kyo S, Takakura M, Tanaka M, et al. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 2000;60:5376-81.
20. Neidle S. Therapeutic Application of Quadruplex Nucleic Acids. Elsevier. 2012
21. Rubis B, Kaczmarek M, Szymanowska N, Galezowska E, et al. The biological activity of G-quadruplex DNA binding papaverine-derived ligand in breast cancer cells. Invest New Drugs. 2009;27:289-96.
22. Kasiappan R, Shen Z, Tse AK, Jinwal U, et al. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J Biol Chem. 2012;287:41297-309.
23. Xiao X, Sidorov IA, Gee J, Lempicki RA, et al. Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005;79:108-17.
24. Purev E, Soprano DR, Soprano KJ. Effect of all-trans retinoic acid on telomerase activity in ovarian cancer cells. J Exp Clin Cancer Res. 2004;23:309-16.
25. Nanni S, Narducci M, Della Pietra L, Moretti F, et al. Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest. 2002;110:219-27.
26. Nautiyal S, DeRisi JL, Blackburn EH. The genome-wide expression response to telomerase deletion in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 2002;99:9316-21.
27. Elmore LW, Rehder CW, Di X, McChesney PA, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem. 2002;277:35509-15.
28. Shammas MA, Koley H, Batchu RB, Bertheau RC, et al. Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer. 2005;4:24.
29. Meyerson M, Counter CM, Eaton EN, Ellisen LW, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785-95.
30. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277:955-9.
31. Giannone RJ, McDonald HW, Hurst GB, Shen RF, et al. The protein network surrounding the human telomere repeat binding factors TRF1, TRF2, and POT1. PLoS One. 2010;5:e12407.
32. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100-10.
33. Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, et al. A human telomeric protein. Science. 1995;270:1663-7.
34. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008;42:301-34.
35. Ye JZ, Donigian JR, van Overbeek M, Loayza D, et al. TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J Biol Chem. 2004;279:47264-71.
36. Wang F, Podell ER, Zaug AJ, Yang Y, et al. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature. 2007;445:506-10.
37. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8:137-42.
38. Wojtyla A, Gladych M, Rubis B. Human telomerase activity regulation. Mol Biol Rep. 2010;38:3339-49.
39. Bellon M, Nicot C. Regulation of telomerase and telomeres: human tumor viruses take control. J Natl Cancer Inst. 2008;100:98-108.
40. Straat K, Liu C, Rahbar A, Zhu Q, et al. Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst. 2009;101:488-97.
41. Fujiki T, Udono M, Kadooka K, Yamashita S, et al. Regulatory mechanisms of human and mouse telomerase reverse transcriptase gene transcription: distinct dependency on c-Myc. Cytotechnology. 2010;62:333-9.
42. Akiyama M, Kawano T, Mikami-Terao Y, Agawa-Ohta M, et al. Erythropoietin activates telomerase through transcriptional and posttranscriptional regulation in human erythroleukemic JAS-REN-A cells. Leuk Res. 2010;35:416-8.
43. Bosc DG, Janknecht R. Regulation of Her2/neu promoter activity by the ETS transcription factor, ER81. J Cell Biochem. 2002;86:174-83.
44. Vageli D, Ioannou MG, Koukoulis GK. Transcriptional activation of hTERT in breast carcinomas by the Her2-ER81-related pathway. Oncol Res. 2009;17:413-23.
45. Goueli BS, Janknecht R. Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol. 2004;24:25-35.
46. Ren H, Zhao T, Wang X, Gao C, et al. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2010;394:59-63.
47. Kunimura C, Kikuchi K, Ahmed N, Shimizu A, et al. Telomerase activity in a specific cell subset co-expressing integrinbeta1/EGFR but not p75NGFR/bcl2/integrin beta4 in normal human epithelial cells. Oncogene. 1998;17:187-97.
48. Misiti S, Nanni S, Fontemaggi G, Cong YS, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol. 2000;20:3764-71.
49. Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996;17:587-609.
50. Gladych M, Wojtyla A, Rubis B. Human telomerase expression regulation. Biochem Cell Biol. 2011;89:359-76.
51. Kyo S, Takakura M, Kanaya T, Zhuo W, et al. Estrogen activates telomerase. Cancer Res. 1999;59:5917-21.
52. Marconett CN, Sundar SN, Tseng M, Tin AS, et al. Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells. Carcinogenesis. 2011;32:1315-23.
53. Zhou C, Liu J. Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells. Biochem Biophys Res Commun. 2003;303:130-6.
54. Xiong J, Fan S, Meng Q, Schramm L, et al. BRCA1 inhibition of telomerase activity in cultured cells. Mol Cell Biol. 2003;23:8668-90.
55. Li H, Lee TH, Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem. 2002;277:20965-73.
56. Ballal RD, Saha T, Fan S, Haddad BR, et al. BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage. J Biol Chem. 2009;284:36083-98.
57. Kanaya T, Kyo S, Hamada K, Takakura M, et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res. 2000;6:1239-47.
58. Toh WH, Kyo S, Sabapathy K. Relief of p53-mediated telomerase suppression by p73. J Biol Chem. 2005;280:17329-38.
59. Jost CA, Marin MC, Kaelin Jr WG. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997;389:191-4.
60. Kaghad M, Bonnet H, Yang A, Creancier L, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809-19.
61. Akiyama M, Hideshima T, Hayashi T, Tai YT, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002;62:3876-82.
62. Li Y, Liu L, Andrews LG, Tollefsbol TO. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer. 2009;125:286-96.
63. Kawagoe J, Ohmichi M, Takahashi T, Ohshima C, et al. Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line. J Biol Chem. 2003;278:43363-72.
64. Martinez-Campa CM, Alonso-Gonzalez C, Mediavilla MD, Cos S, et al. Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett. 2008;268:272-7.
65. Moon DO, Kim MO, Heo MS, Lee JD, et al. Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Arch Pharm Res. 2009;32:1351-60.
66. Kim MO, Moon DO, Kang SH, Heo MS, et al. Pectenotoxin-2 represses telomerase activity in human leukemia cells through suppression of hTERT gene expression and Akt-dependent hTERT phosphorylation. FEBS Lett. 2008;582:3263-9.
67. Moon DO, Kim MO, Nam TJ, Kim SK, et al. Pectenotoxin-2 induces G2/M phase cell cycle arrest in human breast cancer cells via ATM and Chk1/2-mediated phosphorylation of cdc25C. Oncol Rep. 2010;24:271-6.
68. Heaphy CM, Subhawong AP, Gross AL, Konishi Y, et al. Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes. Mod Pathol. 2011;24:194-200.
69. Joseph I, Tressler R, Bassett E, Harley C, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res. 2010;70:9494-504.
70. Papanikolaou V, Iliopoulos D, Dimou I, Dubos S, et al. The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells. Int J Oncol. 2009;35:1141-9.
71. Divella R, Tommasi S, Lacalamita R, Daniele A, et al. Circulating hTERT DNA in early breast cancer. Anticancer Res. 2009;29:2845-9.
72. Phipps SM, Love WK, White T, Andrews LG, et al. Retinoid-induced histone deacetylation inhibits telomerase activity in estrogen receptor-negative breast cancer cells. Anticancer Res. 2009;29:4959-64.
73. Meeran SM, Patel SN, Tollefsbol TO. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One. 2010;5:e11457.
74. Yague E, Arance A, Kubitza L, O'Hare M, et al. Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res. 2007;67:1130-7.
75. Wang J, Liu X, Fang J. Expression and clinical significance of telomerase catalytic subunit gene in lung cancer and its correlations with genes related to drug resistance and apoptosis. Zhonghua Zhong Liu Za Zhi. 1999;21:350-3.
76. Siva AC, Raval-Fernandes S, Stephen AG, LaFemina MJ, et al. Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer. 2001;92:195-202.
77. Kuranaga N, Shinomiya N, Mochizuki H. Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study. BMC Cancer. 2001;1:10.
78. Ji XM, Xie CH, Fang MH, Zhou FX, et al. Efficient inhibition of human telomerase activity by antisense oligonucleotides sensitizes cancer cells to radiotherapy. Acta Pharmacol Sin. 2006;27:1185-91.
79. Chung HK, Cheong C, Song J, Lee HW. Extratelomeric functions of telomerase. Curr Mol Med. 2005;5:233-41.
80. Massard C, Zermati Y, Pauleau AL, Larochette N, et al. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene. 2006;25:4505-14.
81. Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol. 2005;68:779-86.
82. Dong X, Liu A, Zer C, Feng J, et al. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer. 2009;9:133.
83. Poynter KR, Sachs PC, Bright AT, Breed MS, et al. Genetic inhibition of telomerase results in sensitization and recovery of breast tumor cells. Mol Cancer Ther. 2009;8:1319-27.
84. Chen Z, Koeneman KS, Corey DR. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res. 2003;63:5917-25.
85. http://www.geron.com/grn1005
86. Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, et al. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther. 2009;8:2027-35.
87. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, et al. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat. 2006;96:73-81.
88. Tamakawa RA, Fleisig HB, Wong JM. Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner. Cancer Res. 2010;70:8684-94.
89. Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer? Mutat Res. 2012;730:90-7.
90. Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res. 2008;18:725-32.
91. Sjoblom T, Jones S, Wood LD, Parsons DW, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268-74.
92. Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. Breast. 2009;18 Suppl 3:S51-4.
93. Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, et al. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol. 2002;76:12813-22.
94. Knight JS, Cotter 2nd MA, Robertson ES. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. J Biol Chem. 2001;276:22971-8.
95. Furuya M, Tsuji N, Kobayashi D, Watanabe N. Interaction between survivin and aurora-B kinase plays an important role in survivin-mediated up-regulation of human telomerase reverse transcriptase expression. Int J Oncol. 2009;34:1061-8.
96. Xu D, Wang Q, Gruber A, Bjorkholm M, et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene. 2000;19:5123-33.
97. Beitzinger M, Oswald C, Beinoraviciute-Kellner R, Stiewe T. Regulation of telomerase activity by the p53 family member p73. Oncogene. 2006;25:813-26.
98. Wang J, Xie LY, Allan S, Beach D, et al. Myc activates telomerase. Genes Dev. 1998;12:1769-74.
99. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999;21:220-4.
100. Dwyer J, Li H, Xu D, Liu JP. Transcriptional regulation of telomerase activity: roles of the Ets transcription factor family. Ann N Y Acad Sci. 2007;1114:36-47.
101. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093-107.
102. Konnikova L, Simeone MC, Kruger MM, Kotecki M, et al. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res. 2005;65:6516-20.
103. Oh ST, Kyo S, Laimins LA. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol. 2001;75:5559-66.
104. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene. 2002;21:643-9.
105. Kim NW, Piatyszek MA, Prowse KR, Harley CB, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-5.
106. Oh S, Song Y, Yim J, Kim TK. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem. 1999;274:37473-8.
107. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell. 2003;113:881-9.
108. Zhou C, Bae-Jump VL, Whang YE, Gehrig PA, et al. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol Oncol. 2006;101:305-10.
109. McMurray HR, McCance DJ. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J Virol. 2003;77:9852-61.
110. Jagadeesh S, Banerjee PP. Inositol hexaphosphate represses telomerase activity and translocates TERT from the nucleus in mouse and human prostate cancer cells via the deactivation of Akt and PKCalpha. Biochem Biophys Res Commun. 2006;349:1361-7.
111. Goueli BS, Janknecht R. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene. 2003;22:8042-7.
112. Uziel O, Fenig E, Nordenberg J, Beery E, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 2005;92:1881-91.
113. Fujimoto K, Kyo S, Takakura M, Kanaya T, et al. Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res. 2000;28:2557-62.
114. Yang Y, Cai S, Yang L, Yu S, et al. Targeting eradication of malignant cells derived from human bone marrow mesenchymal stromal cells. Exp Cell Res. 2010;316:3329-41.
115. Akutagawa O, Nishi H, Kyo S, Terauchi F, et al. Early growth response-1 mediates downregulation of telomerase in cervical cancer. Cancer Sci. 2008;99:1401-6.
116. Racek T, Mise N, Li Z, Stoll A, et al. C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J Biol Chem. 2005;280:40402-5.
117. Gewin L, Myers H, Kiyono T, Galloway DA. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004;18:2269-82.
118. Lee SH, Kim JW, Oh SH, Kim YJ, et al. IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. FEBS Lett. 2005;579:1027-33.
119. Renaud S, Loukinov D, Bosman FT, Lobanenkov V, et al. CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res. 2005;33:6850-60.
120. Renaud S, Loukinov D, Abdullaev Z, Guilleret I, et al. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 2007;35:1245-56.
121. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, et al. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ Res. 2006;98:e50-9.